Lupus Autoantibody Activates Tumor Immunity and Delivers RNA
Publication Title: A lupus-derived autoantibody that binds to intracellular RNA activates cGAS-mediated tumor immunity and can deliver RNA into cells
Summary
- Question
- This study investigated the potential of a lupus-associated autoantibody, called 4H2, to activate tumor immunity and deliver RNA into cells. The researchers explored how 4H2 binds to intracellular RNA, engages a key immune sensor called cGAS (cyclic GMP-AMP synthase), and enhances immune responses against cancer, particularly glioblastoma, a highly aggressive brain tumor.
- Why it Matters
- Cancer cells often suppress the immune system, making them difficult to target with treatments. This research highlights how a naturally occurring autoantibody from lupus could be repurposed to stimulate the immune system and attack cancer cells. Beyond cancer, the ability of 4H2 to deliver RNA into cells without using viruses could open new possibilities for RNA-based therapies, including vaccines and gene delivery, in a safer and more targeted way.
- Methods
- The researchers used cell culture experiments, animal models, and imaging techniques to study 4H2. They tested its ability to enter cancer cells, bind RNA, and activate cGAS. They also evaluated its effects in mice with glioblastoma, including survival rates and immune cell activity. Additionally, 4H2 was tested for delivering functional RNA into tumors, brain tissue, and muscle.
- Key Findings
- The study found that 4H2 can enter cells by a unique pathway that avoids destruction by cellular compartments. Once inside, it binds RNA and activates cGAS, triggering immune signaling. In glioblastoma models, 4H2 localized to tumors, improved survival in a T cell–dependent manner, and increased immune cell infiltration. It also enhanced the effects of immune checkpoint blockade, a type of cancer immunotherapy. Additionally, 4H2 successfully delivered RNA into cells and tissues, demonstrating its potential for nonviral gene delivery.
- Implications
- These findings suggest that 4H2 could be developed as a dual-purpose therapy: a tool for cancer immunotherapy and a vehicle for delivering RNA-based treatments. In glioblastoma, it may help overcome the tumor's immune-suppressive environment, making other therapies more effective. The study also opens avenues for using 4H2 in RNA-based therapies for conditions beyond cancer, such as genetic disorders or infectious diseases.
- Next Steps
Future research will focus on understanding how 4H2 interacts with cGAS and other cellular pathways. Researchers aim to refine its design to minimize potential side effects, such as immune complex deposition in the kidneys, and explore its use in other cancers or diseases requiring RNA delivery. Clinical trials are necessary to assess its safety and efficacy in humans.
- Funding Information
- This research was supported by the National Institutes of Health (award R01 NS112223). Additional support was provided by an American Cancer Society Institutional Research Grant (no. 58-012-55), Yale Cancer Center Pilot Research Grant, the Colton Center for Autoimmunity at Yale, and the Department of Therapeutic Radiology at Yale School of Medicine.
Full Citation
Chen X, Tang X, Xie Y, Cuffari B, Tang C, Cao F, Gao X, Meng Z, Noble P, Young M, Turk O, Shirali A, Gera J, Nishimura R, Zhou J, Hansen J. A lupus-derived autoantibody that binds to intracellular RNA activates cGAS-mediated tumor immunity and can deliver RNA into cells. Science Signaling 2025, 18: eadk3320-eadk3320. PMID: 40132052, PMCID: PMC12076517, DOI: 10.1126/scisignal.adk3320.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.
Authors
Xiaoyong Chen
First AuthorJames E. Hansen, MD, MS
Last AuthorAssociate Professor of Therapeutic Radiology
Additional Yale School of Medicine Authors
Other Authors
Research Themes
Keywords
Concepts
- systemic lupus erythematosus;
- orthotopic models of glioblastoma;
- necrotic tumor cells;
- pathophysiology of autoimmunity;
- nonviral gene delivery;
- models of glioblastoma;
- tumor immunity;
- orthotopic model;
- T cells;
- lupus erythematosus;
- tumor cells;
- gene delivery;
- animal survival;
- cyclic GMP-AMP synthase;
- immune response;
- autoantibodies;
- therapeutic opportunities;
- cancer treatment;
- promote animal survival;
- deliver RNA;
- immune signaling;
- living mice;
- antibodies;
- cells;
- muscle tissue